The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study
Authors:Andreea-Cristina Paraschiv1,a, Vitalie Vacaras1,2,a, Cristina Nistor1,2, Cristiana Vacaras3, Stefan Strilciuc1 and Dafin F Muresanu1,2
doi: 10.15698/mic2024.04.819
Volume 11, pp. 106 to 115, published 06/04/2024.
1 Department of Neurosciences, Faculty of Medicine, Iuliu Hat,ieganu University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. 2 Neurology Department, Cluj Emergency County Hospital, 400012, ClujNapoca, Romania. 3 Faculty of Medicine, Iuliu Hat,ieganu University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania.
Keywords:
multiple sclerosis, demyelinating autoimmune disorders, gut microbiota, microbiome, brain gut axis, immunomodulation, immunoglobulin Y.
Corresponding Author(s):
Conflict of interest statement:
The authors declare no conflict of interest.
Please cite this article as:
Andreea-Cristina Paraschiv, Vitalie Vacaras, Cristina Nistor, Cristiana Vacaras, Stefan Strilciuc, Dafin F Muresanu (2024). The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study. Microbial Cell 11: 106-115. doi: 10.15698/mic2024.03.819
© 2024 Paraschiv et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Abstract:
Gut microbiota has complex immune functions, related to different pathologies, including multiple sclerosis (MS). This study evaluated the influence of treatments on gut microbiota in people with MS (PwMS). The research comprised 60 participants, including 39 PwMS and 21 healthy controls (HC). Among the PwMS, 20 were prescribed a disease-modifying therapy (DMT), either interferon beta1a or teriflunomide, while 19 received a combination of classical DMT and an immunoglobulin Y (IgY) supplement. For each participant, two sets of gut samples were collected: one at the study’s outset and another after two months. Alpha and beta diversity analyses revealed no significant differences between groups. In comparison to the HC, the MS group exhibited an increase in Prevotella stercorea and a decrease in Faecalibacterium prausnitzii. Following treatment, individuals with MS showed enrichment in Lachnospiraceae and Streptococcus. The second sample, compared to the first one, demonstrated an increase in Bifidobacterium angulatum and a decrease in Oscillospira for individuals with MS. Gut microbiota diversity in PwMS is not significantly different to HC. However, specific taxonomic changes indicate the presence of a dysbiosis state. The use of DMTs and immunoglobulin Y supplements may contribute to alterations in microbial composition, potentially leading to the restoration of a healthier microbiome.